Cargando…

Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma

PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Lin, Cai, Jinquan, Tan, Zixiao, Meng, Xiangqi, Li, Ruiyan, Li, Yang, Jiang, Chuanlu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053882/
https://www.ncbi.nlm.nih.gov/pubmed/33070553
http://dx.doi.org/10.4143/crt.2020.506
_version_ 1783680209033101312
author Lin, Lin
Cai, Jinquan
Tan, Zixiao
Meng, Xiangqi
Li, Ruiyan
Li, Yang
Jiang, Chuanlu
author_facet Lin, Lin
Cai, Jinquan
Tan, Zixiao
Meng, Xiangqi
Li, Ruiyan
Li, Yang
Jiang, Chuanlu
author_sort Lin, Lin
collection PubMed
description PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIALS AND METHODS: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation. RESULTS: We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC(50) of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV(+)propidium iodide(−) cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. CONCLUSION: These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas.
format Online
Article
Text
id pubmed-8053882
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-80538822021-04-29 Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma Lin, Lin Cai, Jinquan Tan, Zixiao Meng, Xiangqi Li, Ruiyan Li, Yang Jiang, Chuanlu Cancer Res Treat Original Article PURPOSE: Isocitrate dehydrogenase 1 (IDH1) mutations are the most common genetic abnormalities in low-grade gliomas and secondary glioblastomas. Glioma patients with these mutations had better clinical outcomes. However, the effect of IDH1 mutation on drug sensitivity is still under debate. MATERIALS AND METHODS: IDH1-R132H mutant cells were established by lentivirus. IDH1-R132H protein expression was confirmed by western blot. The expression of ataxia telangiectasia mutated (ATM) signaling pathway and apoptosis-related proteins were detected by immunofluorescence and western blot. Temozolomide (TMZ) induced cell apoptosis was detected by flow cytometry. Tumor cell proliferation was detected by Cell Counting Kit-8. In vivo nude mice were used to confirm the in vitro roles of IDH1 mutation. RESULTS: We established glioma cell lines that expressed IDH1-R132H mutation stably. We found that TMZ inhibited glioma cells proliferation more significantly in IDH1 mutant cells compared to wild type. The IC(50) of TMZ in IDH1-R132H mutant group was less than half that of wild-type group (p < 0.01). TMZ significantly induced more DNA damage (quantification of γH2AX expression in IDH1 mutation vs. wild type, p < 0.05) and apoptosis (quantification of AnnexinV(+)propidium iodide(−) cells in IDH1 mutation versus wild type, p < 0.01) in IDH1 mutant gliomas compared to wild-type gliomas. The ATM-associated DNA repair signal was impaired in IDH1 mutant cells. Inhibiting the ATM/checkpoint kinase 2DNA repair pathway further sensitized IDH1 mutant glioma cells to chemotherapy. We found that IDH1 mutation significantly inhibited tumor growth in vivo (the tumor size was analyzed statistically, p < 0.05). Moreover, we confirmed that gliomas with IDH1 mutation were more sensitive to TMZ in vivo compared to wild type significantly and the results were consistent with the in vitro experiment. CONCLUSION: These results provide evidence that combination of TMZ and ATM inhibitor enhances the antitumor effect in IDH1 mutant gliomas. Korean Cancer Association 2021-04 2020-10-13 /pmc/articles/PMC8053882/ /pubmed/33070553 http://dx.doi.org/10.4143/crt.2020.506 Text en Copyright © 2021 by the Korean Cancer Association https://creativecommons.org/licenses/by-nc/4.0/This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lin, Lin
Cai, Jinquan
Tan, Zixiao
Meng, Xiangqi
Li, Ruiyan
Li, Yang
Jiang, Chuanlu
Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
title Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
title_full Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
title_fullStr Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
title_full_unstemmed Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
title_short Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma
title_sort mutant idh1 enhances temozolomide sensitivity via regulation of the atm/chk2 pathway in glioma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053882/
https://www.ncbi.nlm.nih.gov/pubmed/33070553
http://dx.doi.org/10.4143/crt.2020.506
work_keys_str_mv AT linlin mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma
AT caijinquan mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma
AT tanzixiao mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma
AT mengxiangqi mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma
AT liruiyan mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma
AT liyang mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma
AT jiangchuanlu mutantidh1enhancestemozolomidesensitivityviaregulationoftheatmchk2pathwayinglioma